The fibrinolytic enzyme system: Basic principles and links to venous and arterial thrombosis

Hematology/Oncology Clinics of North America

Volumn 14, Issue 2, 2000, Pages 325-338

  Wiman, Björn ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN; PLASMINOGEN ACTIVATOR; PROTEINASE INHIBITOR; STREPTOKINASE;

ARTERY THROMBOSIS; CARDIOVASCULAR RISK; DEEP VEIN THROMBOSIS; FIBRINOLYSIS; GENOTYPE; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; REVIEW;

EID: 0034011175     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70136-2     Document Type: Article

References (75)

1. P.A. Andreasen L. Kjoller L. Christensen The urokinase-type plasminogen activator system in cancer metastasis: A review Int J Cancer 72 1997 1
2. F. Andreotti G.J. Davies D.R. Hackett Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke Am J Cardiol 62 1988 635
3. Angles Cano E. J.C. Gris S. Loyau Familial association of high levels of histidine-rich glycoprotein and plasminogen activator inhibitor-1 with venous thromboembolism J Lab Clin Med 121 1993 646
4. N. Aoki Y. Sakata M. Matsuda Fibrinolytic states in a patient with congenital deficiency of alpha 2-plasmin inhibitor Blood 55 1980 48
5. N. Aoki Physiological endogenous fibrinolysis: Its congenital abnormalities Progress in Fibrinolysis 6 1983 3
6. N.A. Booth A. Croll B. Bennet The activity of plasminogen activator inhibitor-1 (PAI-1) of human platelets Fibrinolysis 4 1990 138
7. BaÅvenholm P. deFaire U. C. Landou Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipid metabolism and to impaired fibrinolytic function Eur Heart J 19 1998 402
8. P. Carmeliet L. Schoonjans L. Kieckens Physiological consequences of loss of plasminogen activator gene function in mice Nature 368 1994 419
9. F.J. Castellino Biochemistry of human plasminogen Semin Thromb Hemostas 10 1984 18
10. J. Chmielewska M. Rånby B. Wiman Kinetics of the inhibition of plasminogen activators by the plasminogen activator inhibitor. Evidence for “second site” interactions Biochem J 251 1987 327
11. J. Chmielewska M. Rånby B. Wiman Evidence for a rapid inhibitor to tissue plasminogen activator in plasma Thromb Res 31 1983 427
12. D. Collen The plasminogen (fibrinolytic) system Thromb Haemost 82 1999 259
13. M. Colucci J.A. Paramo D. Collen Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation J Clin Invest 75 1985 818
14. M. Cortellaro E. Cofrancesco C. Boscheti Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients–a case-control study Arteriosclerosis Thrombosis 13 1993 1412
15. S.J. Dawson B. Wiman A. Hamsten The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells J Biol Chem 268 1993 10739
16. C.J.M. Doggen R.M. Bertina V.M. Cats The 4G/5G polymorphism in the plasminogen activator gene is not associated with myocardial infarction Thromb Haemost 82 1999 115
17. J.J. Emeis The control of tPA and PAI-1 secretion from the vessel wall Vascular Medicine Review 6 1995 153
18. L.A. Erickson G.J. Fici J.E. Lund Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene Nature 346 1990 74
19. B. Eriksson E. Eriksson Gyzander E. Thrombosis after hip replacement, relationship to the fibrinolytic system Acta Orthop Scand 60 1989 59
20. P. Eriksson B. Kallin van't Hooft F.M. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction Proc Natl Acad Sci U S A 92 1995 1851
21. T.D. Gelehrter P.A. Barouski-Miller P.L. Coleman Hormonal regulation of plasminogen activator in rat hepatoma cells Mol Cell Biochem 11 1983 53 54
22. W. Gunzler G. Steffens F. Ötting Structural relationship between human high and low molecular mass urokinase Hoppe-Zeyler's Z Physiol Chem 363 1982 1155
23. Hamsten A. de Faire U. G. Walldius Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction Lancet 2 1987 3
24. A. Hamsten B. Wiman de Faire U. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction N Engl J Med 313 1985 1557
25. C. Hekman D. Loskutoff Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants J Biol Chem 260 1985 11581
26. C. Held P. Hjemdahl N. Rehnqvist Haemostatic markers, inflammatory parameters and lipids in male and female patients in the Angina Prognosis Study in Stockholm (APSIS). A comparison with healthy controls J Intern Med 241 1997 59 69
27. C. Held P. Hjemdahl N. Rehnqvist Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with Verapamil or Metoprolol Circulation 95 1997 2380
28. M. Hoylaerts D.C. Rijken H.R. Lijnen Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin J Biol Chem 257 1982 2912
29. S. Isacsson I.M. Nilsson Defective fibrinolysis in blood and vein walls in recurrent idiopathic venous thrombosis Eur J Surg 138 1972 313
30. J.H. Jansson T.K. Nilsson B.O. Olofsson Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris Eur Heart J 12 1991 157
31. J.H. Jansson B.O. Olofsson T.K. Nilsson Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up Circulation 88 1993 2030
32. I. Juhan-Vague M.C. Alessi Regulation of fibrinolysis in the development of atherothrombosis: Role of adipose tissue Thromb Haemost 82 1999 832
33. I. Juhan-Vague S.D.M. Pyke M.C. Alessi Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: ECAT Group. European Concerted Action Thrombosis and Disabilities Study Circulation 94 1996 2057
34. R. Junker J. Heirich H. Schulte Plasminogen activator inhibitor-1 4G/5G polymorphism and factor V Q506 mutation are not associated with myocardial infarction in young men Blood Coagul Fibrinolysis 9 1998 597
35. E.K.O. Kruithof C. Tran-Thang A. Ransijn Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma Blood 64 1984 907
36. E.K.O. Kruithof C. Tran-Thang F. Bachman Studies on the release of a plasminogen activator inhibitor by human platelets Thromb Haemost 55 1986 201
37. E.K.O. Kruithof C. Tran-Thang F. Bachmann The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase Thromb Haemost 55 1986 65
38. W. Laug Vascular smooth muscle cells inhibit the plasminogen activators secreted by endothelial cells Thromb Haemost 53 1985 165
39. M.H. Lee E. Vosburgh K. Anderson Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding Blood 81 1993 2357
40. T.L. Lindahl O. Sigurdardottir B. Wiman Stability of plasminogen activator inhibitor 1 (PAI-1) Thromb Haemost 62 1989 748
41. Loskutoff D.J. van Mourik J.A. L.A. Erickson Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells Proc Natl Acad Sci U S A 80 1983 2956
42. G. Mellbring S. Dahlgren B. Wiman Relationship between preoperative status of the fibrinolytic system and occurrence of deep vein thrombosis after major abdominal surgery Thromb Res 39 1985 157
43. G. Mellbring S. Dahlgren B. Wiman Plasma fibrinolytic activity in patients undergoing major abdominal surgery Eur J Surg 151 1985 109
44. K. Nagendra N. Reddy G. Markus Esterase activities in the zymogen moiety of the streptokinase-plasminogen complex J Biol Chem 249 1974 4851
45. M.E. Nesheim TAFI Fibrinolysis and Proteolysis 13 1999 72
46. F. Noorman D.C. Rijken Regulation of tissue-type plasminogen activator concentrations by clearance via the mannose receptor and other receptors Fibrinolysis and Proteolysis 11 1997 173
47. A. Nordenhem B. Wiman Plasminogen activator inhibitor-1 (PAI-1) content in platelets from healthy individuals, genotyped for the 4G/5G polymorphism in the PAI-1 gene Scandinavian Journal of Laboratory and Clinical Investigation 57 1997 453
48. A. Nordenhem B. Wiman Tissue plasminogen activator (tPA) antigen in plasma: Correlation with different tPA/inhibitor complexes Scandinavian Journal of Laboratory and Clinical Investigation 58 1998 475
49. N. Ossei-Gerning M.W. Mansfield M.H. Stickland Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to history of myocardial infarction in patients characterised by coronary angiography Arterioscler Thromb Vasc Biol 17 1997 33
50. Pannekoek De Fries C. van Zonneveld A.J. Mutants of human tissue-type plasminogen activator (t-PA): Structural and functional properties Fibrinolysis 2 1988 123 132
51. J.A. Paramo M.J. Alfaro E. Rocha Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor—Relationship to deep vein thrombosis and influence of prophylaxis Thromb Haemost 54 1985 713
52. O.D. Pedersen J. Gram J. Jespersen Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease Thromb Haemost 73 1995 835
53. C. Reutervall J. Hallqvist A. Ahlbom Higher relative, but lower absolute risks of myocardial infarction in women than in men: Analysis of some major risk factors in the SHEEP study J Intern Med 246 1999 161
54. P.M. Ridker C.H. Hennekens K. Lindpaintner Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of plasminogen activator inhibitor gene in a large cohort of US men Circulation 95 1997 59
55. P.M. Ridker P.E. Vaughan M.J. Stampfer Endogenous tissue-type plasminogen activator and risk of myocardial infarction Lancet 341 1993 1165
56. M. Rånby N. Bergsdorf T. Nilsson Enzymatic properties of the one- and two-chain forms of tissue plasminogen activator Thromb Res 27 1982 175
57. M. Rånby Studies on the kinetics of plasminogen activation by tissue plasminogen activator Biochim Biophys Acta 704 1982 461
58. Y. Sakata N. Aoki Cross-linking of alpha2-plasmin inhibitor to fibrin by fibrin-stabilizing factor J Clin Invest 65 1980 290
59. F. Samad K. Yamamoto D.J. Loskutoff Distribution and regulation of plasminogen activator inhibitor 1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide J Clin Invest 97 1996 37
60. M.T. Sartori B. Wiman S. Vettore 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis Thromb Haemost 80 1998 956
61. S Schulman, B Wiman, The significance of hypofibrinolysis for the risk of recurrence of venous tromboembolism. Thromb Haemost, in press.
62. O.A. Sodeinde Y.V.B.K. Subrahmanyam K. Stark A surface protease and the invasive character of plaque Science 258 1992 1004
63. Stringer H.A.R. van Swieten P. H.F.G. Heijnen Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the chandler loop Arteriosclerosis Thromb Vasc Biol 14 1994 1452
64. A.M. Thogersen J.H. Jansson K. Boman High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women—Evidence for the fibrinolytic system as an independent primary risk factor Circulation 98 1998 2241
65. S.G. Thompson J. Kienast S.D.M. Pyke Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris N Engl J Med 322 1995 635
66. S.R. Torr-Brown B.E. Sobel Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets Thromb Res 72 1993 413
67. J.I. Weitz R.J. Steward J.C. Fredenburgh Mechanism of action of plasminogen activators Thromb Haemost 82 1999 974
68. B. Wiman D. Collen On the molecular mechanisms of physiological fibrinolysis Nature 272 1978 549
69. B. Wiman P. Wallén The specific interaction between plasminogen and fibrin. A physiological role of the lysine binding site in plasminogen Thromb Res 10 1977 213
70. B. Wiman D. Collen On the kinetics of the reaction between human antiplasmin and plasmin Eur J Biochem 84 1978 573
71. 2-antiplasmin complex in plasma–a global fibrinolytic assay Thromb Haemost 69 1993 1091
72. Wiman B, Andersson T, Hallqvist J, et al: Plasma levels of tPA/PAI-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the SHEEP study. Arteriosclerosis, Thrombosis, and Vascular Biology, in press
73. T.C. Wun L. Ossowski E. Reich A proenzyme form of human urokinase J Biol Chem 257 1982 7262
74. S. Ye F.R. Green P.Y. Scarabin The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study Thromb Haemost 74 1995 837
75. B. Åstedt I. Lecander T. Ny The placental type plasminogen activator inhibitor, PAI-2 Fibrinolysis 1 1987 203